Advertisement

Clinical Rheumatology

, Volume 30, Issue 1, pp 139–144 | Cite as

Active Paget’s disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature

  • Lamprini Gkouva
  • Maria AndrikoulaEmail author
  • Vasilis Kontogeorgakos
  • Dionysios J. Papachristou
  • Agathocles Tsatsoulis
Case Report

Abstract

Paget’s disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, skeletal deformities, and other complications leading to bone pain and significant disability. It can involve one or more areas in a single bone (monostotic) or multiple bones (polyostotic). Most of the time the disease is asymptomatic and the diagnosis is made incidentally by increased levels of bone metabolism markers, especially alkaline phosphatase and is confirmed by specific findings in radiographs and radionuclide bone scan. In this report, we describe the case of a 65-year-old female with clinical and radiological findings of active Paget’s disease of bone, but with absence of abnormal biochemical markers. The patient was given a dose of 5 mg zoledronic acid intravenously with significant clinical improvement within the next 6 months. The present case not only shows that Paget’s disease of bone can occur in the setting of normal markers of bone metabolism but also that, in such cases, the response to treatment can be monitored by improvement in the clinical picture or by correct evaluation of the imaging findings.

Keywords

Alkaline phosphatase Biochemical markers Paget’s disease 

Notes

Disclosures

None.

References

  1. 1.
    Paget J (1877) On a form of chronic inflammation of bones. Trans Med Chir Soc Lond 60:37–63Google Scholar
  2. 2.
    Siris ES, Lyles KW, Singer FR, Meunier PJ (2001) A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res 16:1379–1387CrossRefPubMedGoogle Scholar
  3. 3.
    Kanis J (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. Martin Dunitz, LondonGoogle Scholar
  4. 4.
    Altman R (2002) Paget’s disease of bone. In: Coe FL, Favus MJ (eds) Disorders of bone and mineral metabolism, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 985–1020Google Scholar
  5. 5.
    Doyle T, Gunn J, Anderson G, Gill M, Cundy T (2002) Paget’s disease in New Zealand: evidence for declining prevalence. Bone 31:616–619CrossRefPubMedGoogle Scholar
  6. 6.
    Van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471CrossRefPubMedGoogle Scholar
  7. 7.
    Cooper C, Dennison E, Schafheutle K, Kellingray S, Guyer P, Barker D (1999) Epidemiology of Paget’s disease of bone. Bone 24(5 Suppl):3S–5SCrossRefPubMedGoogle Scholar
  8. 8.
    Siris ES (1996) Paget’s disease of bone. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 3rd edn. Lippincott-Raven, Philadelphia, pp 409–419Google Scholar
  9. 9.
    Tiegs RD (1997) Paget’s disease of bone: indications for treatment and goals of therapy. Clin Ther 19:1309–1329CrossRefPubMedGoogle Scholar
  10. 10.
    Davie M, Davies M, Francis R, Fraser W, Hosking D, Transley R (1999) Paget’s disease of bone: a review of 889 patients. Bone 24(5 Suppl):11S–12SCrossRefPubMedGoogle Scholar
  11. 11.
    Hadjipavlou A, Lander P (1991) Paget’s disease of the spine. J Bone Joint Surg Am 73:1376–1381PubMedGoogle Scholar
  12. 12.
    Barker DJ (1984) The epidemiology of Paget’s disease of bone. Br Med Bull 40:396–400PubMedGoogle Scholar
  13. 13.
    Mee AP (1999) Paramyxoviruses and Paget’s disease: the affirmative view. Bone 24(5 Suppl):19S–21SCrossRefPubMedGoogle Scholar
  14. 14.
    Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Lenenstien MA, Shanks CA, Gregg G, Al-Lozi MT, Miller T, Rakowicz W, Lopate G, Florence J, Glosser G, Simmons Z, Morris JC, Whyte MP, Pestronk A, Kimonis VE (2001) Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone and frontotemporal dementia. Mol Genet Metab 74:458–475CrossRefPubMedGoogle Scholar
  15. 15.
    Hocking L, Slee F, Haslam SI, Cundy T, Nicholson G, van Hul W, Ralston SH (2000) Familial Paget’s disease of bone: patterns of inheritance and frequency of linkage to chromosome 18 q. Bone 26:577–580CrossRefPubMedGoogle Scholar
  16. 16.
    Whyte MP (2006) Paget’s disease of bone. NEJM 355:593–600CrossRefPubMedGoogle Scholar
  17. 17.
    Helfrich MH, Hobson RP, Grabowski PS et al (2000) A negative search for a paramyxoviral etiology of Paget’s disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15:2315–2329CrossRefPubMedGoogle Scholar
  18. 18.
    Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH (2002) Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics 22:1191–1216PubMedGoogle Scholar
  19. 19.
    Singh A, Rana K (2006) Paget’s disease with an unusual presentation: case report. Journal of the Indian Academy of Geriatrics 2(2):74–77Google Scholar
  20. 20.
    Alvarez L, Guanabens N, Penis P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Rivera-Fillat F, Ballesta AM (1995) Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res 10:458–465CrossRefPubMedGoogle Scholar
  21. 21.
    Selby PL, Davie MWJ, Ralston H et al (2002) Guidelines on the management of Paget’s disease of bone. Bone 31:10–19CrossRefGoogle Scholar
  22. 22.
    Shankar S, Hosking DJ (2006) Biochemical assessment of Paget’s disease of bone. J Bone Miner Res 21(Suppl2):P22–P27CrossRefPubMedGoogle Scholar
  23. 23.
    Sinigaglia L, Varenna M, Binelli L, Beltrametti P, Yucchi F, Arrigoni M, Frignani S, Abbiati G (1997) Serum levels of pyridinium crosslinks in postmenopausal women and in Paget’s disease of bone. Calcif Tissue Int 61:279–284CrossRefPubMedGoogle Scholar
  24. 24.
    Uebelhart D, Gineyts E, Chapuy M, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: anew marker of bone resorption in metabolic bone disease. Bone Miner 8:87–96CrossRefPubMedGoogle Scholar
  25. 25.
    Fogelman I, Carr D, Boyle IT (1981) The role of bone scanning in Paget’s disease. Metab Bone Dis Relat Res 3:243–254CrossRefPubMedGoogle Scholar
  26. 26.
    Smith R (1999) Paget’s disease of bone: past and present. Bone 24(5 Suppl):1S–2SCrossRefPubMedGoogle Scholar
  27. 27.
    Seton M, Krane S (2007) Use of zoledronic acid in the treatment of Paget’s disease. Ther Clin Risk Manag 3(5):913–918PubMedGoogle Scholar
  28. 28.
    Fleisch H (2002) Development of biphosphonates. Breast Cancer Res 4:30–34CrossRefPubMedGoogle Scholar
  29. 29.
    Hosking D (2006) Pharmacological therapy of Paget’s and other metabolic bone diseases. Bone 38(2 Suppl 2):S3–S7CrossRefPubMedGoogle Scholar
  30. 30.
    Widler L, Jaeggi KA, Glatt M et al (2002) Highly potent geminal biphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 45:3721–3738CrossRefPubMedGoogle Scholar
  31. 31.
    Buckler H, Fraser W, Hosking D et al (1999) Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study. Bone 24:81S–85SCrossRefPubMedGoogle Scholar
  32. 32.
    Chung G, Keen RW (2003) Zoledronate treatment in active Paget’s disease. Ann Rheum Dis 62:275–276CrossRefPubMedGoogle Scholar
  33. 33.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22(1):142–148CrossRefPubMedGoogle Scholar
  34. 34.
    Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH (2007) Clinical determinants of quality of life in Paget’s disease of bone. Calcif Tissue Int 80(1):1–9CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Lamprini Gkouva
    • 1
  • Maria Andrikoula
    • 1
    Email author
  • Vasilis Kontogeorgakos
    • 2
  • Dionysios J. Papachristou
    • 3
    • 4
  • Agathocles Tsatsoulis
    • 1
  1. 1.Department of EndocrinologyUniversity Hospital of IoanninaIoanninaGreece
  2. 2.Department of OrthopaedicsGeneral Hospital of VolosVolosGreece
  3. 3.Department of Histology and EmbryologyUniversity of Patras, School of MedicinePatrasGreece
  4. 4.Department of PathologyUniversity of Pittsburgh, School of MedicinePittsburghUSA

Personalised recommendations